FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4383227312> ?p ?o ?g. }

• W4383227312 abstract "Conservative management is an option for prostate cancer (PCa) patients either with the objective of delaying or even avoiding curative therapy, or to wait until palliative treatment is needed. PIONEER, funded by the European Commission Innovative Medicines Initiative, aims at improving PCa care across Europe through the application of big data analytics.To describe the clinical characteristics and long-term outcomes of PCa patients on conservative management by using an international large network of real-world data.From an initial cohort of >100 000 000 adult individuals included in eight databases evaluated during a virtual study-a-thon hosted by PIONEER, we identified newly diagnosed PCa cases (n = 527 311). Among those, we selected patients who did not receive curative or palliative treatment within 6 mo from diagnosis (n = 123 146).Patient and disease characteristics were reported. The number of patients who experienced the main study outcomes was quantified for each stratum and the overall cohort. Kaplan-Meier analyses were used to estimate the distribution of time to event data.The most common comorbidities were hypertension (35-73%), obesity (9.2-54%), and type 2 diabetes (11-28%). The rate of PCa-related symptomatic progression ranged between 2.6% and 6.2%. Hospitalization (12-25%) and emergency department visits (10-14%) were common events during the 1st year of follow-up. The probability of being free from both palliative and curative treatments decreased during follow-up. Limitations include a lack of information on patients and disease characteristics and on treatment intent.Our results allow us to better understand the current landscape of patients with PCa managed with conservative treatment. PIONEER offers a unique opportunity to characterize the baseline features and outcomes of PCa patients managed conservatively using real-world data.Up to 25% of men with prostate cancer (PCa) managed conservatively experienced hospitalization and emergency department visits within the 1st year after diagnosis; 6% experienced PCa-related symptoms. The probability of receiving therapies for PCa decreased according to time elapsed after the diagnosis." @default.
• W4383227312 created "2023-07-06" @default.
• W4383227312 creator A5003951535 @default.
• W4383227312 creator A5004091567 @default.
• W4383227312 creator A5007781322 @default.
• W4383227312 creator A5008809342 @default.
• W4383227312 creator A5014337725 @default.
• W4383227312 creator A5014773041 @default.
• W4383227312 creator A5015634061 @default.
• W4383227312 creator A5019353148 @default.
• W4383227312 creator A5023266580 @default.
• W4383227312 creator A5024868620 @default.
• W4383227312 creator A5025690030 @default.
• W4383227312 creator A5025958936 @default.
• W4383227312 creator A5026953825 @default.
• W4383227312 creator A5027189955 @default.
• W4383227312 creator A5031545389 @default.
• W4383227312 creator A5031550729 @default.
• W4383227312 creator A5032134243 @default.
• W4383227312 creator A5036639639 @default.
• W4383227312 creator A5036906000 @default.
• W4383227312 creator A5037837341 @default.
• W4383227312 creator A5039867286 @default.
• W4383227312 creator A5041333542 @default.
• W4383227312 creator A5043615906 @default.
• W4383227312 creator A5045529308 @default.
• W4383227312 creator A5047149018 @default.
• W4383227312 creator A5048658335 @default.
• W4383227312 creator A5048994608 @default.
• W4383227312 creator A5050157873 @default.
• W4383227312 creator A5052809243 @default.
• W4383227312 creator A5053854071 @default.
• W4383227312 creator A5056479059 @default.
• W4383227312 creator A5057676234 @default.
• W4383227312 creator A5060088677 @default.
• W4383227312 creator A5061631638 @default.
• W4383227312 creator A5063466486 @default.
• W4383227312 creator A5064535931 @default.
• W4383227312 creator A5066281730 @default.
• W4383227312 creator A5070518164 @default.
• W4383227312 creator A5070550028 @default.
• W4383227312 creator A5071876598 @default.
• W4383227312 creator A5072545259 @default.
• W4383227312 creator A5077678731 @default.
• W4383227312 creator A5079445684 @default.
• W4383227312 creator A5085107471 @default.
• W4383227312 creator A5086845605 @default.
• W4383227312 date "2023-07-01" @default.
• W4383227312 modified "2023-10-18" @default.
• W4383227312 title "Clinical Characterization of Patients Diagnosed with Prostate Cancer and Undergoing Conservative Management: A PIONEER Analysis Based on Big Data" @default.
• W4383227312 cites W2015712245 @default.
• W4383227312 cites W2024401484 @default.
• W4383227312 cites W2120729896 @default.
• W4383227312 cites W2132611552 @default.
• W4383227312 cites W2159207240 @default.
• W4383227312 cites W2163098725 @default.
• W4383227312 cites W2548278160 @default.
• W4383227312 cites W2772729245 @default.
• W4383227312 cites W2774743973 @default.
• W4383227312 cites W2894751050 @default.
• W4383227312 cites W2905153461 @default.
• W4383227312 cites W2917520831 @default.
• W4383227312 cites W2969901322 @default.
• W4383227312 cites W3004465995 @default.
• W4383227312 cites W3018527648 @default.
• W4383227312 cites W3097158220 @default.
• W4383227312 cites W3171514090 @default.
• W4383227312 cites W3211281229 @default.
• W4383227312 cites W3211460278 @default.
• W4383227312 cites W4229451263 @default.
• W4383227312 cites W4283693701 @default.
• W4383227312 cites W4309622545 @default.
• W4383227312 doi "https://doi.org/10.1016/j.eururo.2023.06.012" @default.
• W4383227312 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37414703" @default.
• W4383227312 hasPublicationYear "2023" @default.
• W4383227312 type Work @default.
• W4383227312 citedByCount "0" @default.
• W4383227312 crossrefType "journal-article" @default.
• W4383227312 hasAuthorship W4383227312A5003951535 @default.
• W4383227312 hasAuthorship W4383227312A5004091567 @default.
• W4383227312 hasAuthorship W4383227312A5007781322 @default.
• W4383227312 hasAuthorship W4383227312A5008809342 @default.
• W4383227312 hasAuthorship W4383227312A5014337725 @default.
• W4383227312 hasAuthorship W4383227312A5014773041 @default.
• W4383227312 hasAuthorship W4383227312A5015634061 @default.
• W4383227312 hasAuthorship W4383227312A5019353148 @default.
• W4383227312 hasAuthorship W4383227312A5023266580 @default.
• W4383227312 hasAuthorship W4383227312A5024868620 @default.
• W4383227312 hasAuthorship W4383227312A5025690030 @default.
• W4383227312 hasAuthorship W4383227312A5025958936 @default.
• W4383227312 hasAuthorship W4383227312A5026953825 @default.
• W4383227312 hasAuthorship W4383227312A5027189955 @default.
• W4383227312 hasAuthorship W4383227312A5031545389 @default.
• W4383227312 hasAuthorship W4383227312A5031550729 @default.
• W4383227312 hasAuthorship W4383227312A5032134243 @default.
• W4383227312 hasAuthorship W4383227312A5036639639 @default.
• W4383227312 hasAuthorship W4383227312A5036906000 @default.
• W4383227312 hasAuthorship W4383227312A5037837341 @default.
• W4383227312 hasAuthorship W4383227312A5039867286 @default.
• W4383227312 hasAuthorship W4383227312A5041333542 @default.

• next